Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 130

Results For "IND"

6837 News Found

FDA nod to Boehringer Ingelheim's heart disease treatment for dogs 'Vetmedin'
Drug Approval | January 23, 2026

FDA nod to Boehringer Ingelheim's heart disease treatment for dogs 'Vetmedin'

VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs


Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies
R&D | January 23, 2026

Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies

The partnership initially will focus on cardiovascular and kidney diseases


Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline
News | January 23, 2026

Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline

The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025


iRegene’s Parkinson’s therapy gains FDA designation
News | January 21, 2026

iRegene’s Parkinson’s therapy gains FDA designation

The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases


Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy
News | January 21, 2026

Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy

The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026


Lupin and Galenicum ink license and supply agreement for semaglutide in 23 countries
News | January 21, 2026

Lupin and Galenicum ink license and supply agreement for semaglutide in 23 countries

Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally


Neurizon locks in global trademark protection across key pharma markets
News | January 21, 2026

Neurizon locks in global trademark protection across key pharma markets

The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions


Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%
News | January 21, 2026

Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%

In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.